San Antonio Breast Cancer Symposium | Conference

Frontline Ribociclib/Letrozole Improves OS in Postmenopausal HR+ Breast Cancer, Irrespective of Metastatic Site

December 8th 2021

First-line treatment with ribociclib/letrozole improved overall survival over placebo in patients with postmenopausal, hormone receptor–positive, HER2-negative advanced breast cancer, irrespective of metastatic site, number of sites, or prior (neo)adjuvant chemotherapy and endocrine therapy.

Standard IHC Assays Show Poor Accuracy in Identifying Low HER2 Expression in Breast Cancer

December 8th 2021

Survey data collected from more than 1400 laboratories around the world have demonstrated poor agreement in the evaluation of patients with breast cancer who have a low HER2 immunohistochemistry score of 0 or 1+ using standard HER2 assays.

Higher Oncotype DX Scores Predict for Improved Endocrine Therapy Compliance in ER+ Breast Cancer

December 8th 2021

Higher Oncotype DX recurrence scores were associated with prolonged persistence to 5 years of endocrine therapy vs lower Oncotype DX recurrence scores in patients with low-risk, estrogen receptor-positive/progesterone receptor–positive breast cancer, according to findings from a retrospective review.

Dr. Fernandez on the Results of a Study Examining Low HER2 Expression in Breast Cancer

December 8th 2021

Aileen I. Fernandez, PhD, discusses the results of a study examining low HER2 expression in breast cancer.

Datopotamab Deruxtecan Produces Encouraging Clinical Activity in Advanced TNBC

December 8th 2021

Datopotamab deruxtecan showed highly encouraging and durable efficacy through overall response rates in patients with advanced or metastatic triple-negative breast cancer.

Entinostat/Exemestane Improves PFS in Chinese Patients With Advanced HR+ Breast Cancer

December 7th 2021

The combination of entinostat and exemestane led to a significant improvement in progression-free survival compared with placebo and exemestane in Chinese patients with advanced hormone receptor–positive breast cancer.

Adjuvant Pembrolizumab Sustains Benefit Across TNBC Subgroups

December 7th 2021

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab resulted in a statistically significant and clinically meaningful improvement in event-free survival in patients with early-stage triple negative breast cancer.

Final Results from PALLAS Study Confirm Lack of Benefit in Adding Palbociclib to ET in Early HR+, HER2- Breast Cancer

December 7th 2021

Adding adjuvant palbociclib to standard endocrine therapy did not improve outcomes in patients with stage II to III hormone receptor–positive, HER2-negative early breast cancer.

Pembrolizumab Plus Chemotherapy Represents New Standard of Care for Metastatic TNBC With PD-L1 CPS ≥10

December 7th 2021

Pembrolizumab plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival and overall survival vs chemotherapy alone in patients with previously untreated, locally recurrent, inoperable, or metastatic triple-negative breast cancer who have a PD-L1 combined positive score of 10 or higher.

Adjuvant Metformin Does Not Improve Survival Outcomes in Early Breast Cancer

December 7th 2021

Metformin failed to improve invasive disease-free survival or overall survival when used as adjuvant treatment in patients with early breast cancer, irrespective of estrogen or progesterone receptor status.

Tamoxifen May Increase Risk of Secondary Uterine Cancer In Select Patients With Primary Breast Cancer

December 7th 2021

Patients with primary breast cancer who developed secondary uterine cancer following treatment with tamoxifen may have had disease driven by PI3K-pathway activation.

Breast Cancer–Related Lymphedema Occurs More Often in Black Women Vs White Women

December 7th 2021

The highest incidence of lymphedema observed was among the Black women with a 24-month lymphedema rate of 39.4%.

Elacestrant Significantly Improves PFS in Advanced ER+ Breast Cancer, Including ESR1-Mutant Subtype

December 7th 2021

The selective estrogen receptor degrader elacestrant (RAD1901) led to a 30% reduction in the risk of disease progression or death compared with standard of care in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer who previously received CDK4/6 inhibition.

Matched Targeted Therapy Improves PFS Through Multigene Sequencing in Metastatic Breast Cancer

December 7th 2021

Genomic alterations identified through multigene sequencing, classified in the I/II tiers of the ESMO Scale of Actionability of Molecular Targets, and paired with matching targeted therapy led to a significant improvement in progression-free survival vs maintenance chemotherapy in patients with HER2-negative metastatic breast cancer.

Single-Cell Spatial Analysis for Immunotherapy Response Prediction in Early TNBC Shows Promise

December 7th 2021

Imaging mass cytometry at the single-cell level showed potential as an immunotherapy response prediction tool in early triple-negative breast cancer.

Neratinib Improves PFS in HER2+ Breast Cancer With Brain Metastases

December 14th 2020

December 14, 2020 - The combination of neratinib and capecitabine showed a 34% reduction in the risk of disease progression or death compared with lapatinib and capecitabine in patients with HER2-positive breast cancer who had central nervous system metastases at baseline.

Dr. Hamilton on the Mechanism of Action of OP-1250 in HR+/HER2- Metastatic Breast Cancer

December 12th 2020

Erika P. Hamilton, MD, discusses the mechanism of action of OP-1250 in patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

Dr. Harbeck on Ki-67 as a Biomarker for Identifying High-Risk Early Breast Cancer

December 12th 2020

Nadia Harbeck, MD, PhD, discusses Ki-67 as a biomarker for identifying patients with high-risk early breast cancer who received treatment on the monarchE trial.

Tucatinib Triplet Prolongs Time to Deterioration of HRQOL in HER2+ Breast Cancer With Brain Metastases

December 12th 2020

December 11, 2020 - Tucatinib in combination with trastuzumab and capecitabine significantly prolonged the time to deterioration of health-related quality of life in patients with HER2- positive metastatic breast cancer with brain metastases.

Addition of 1-Year Palbociclib to Endocrine Therapy Fails to Improve iDFS in High-Risk HR+/HER2- Breast Cancer

December 11th 2020

December 11, 2020 - The addition of 1 year of palbociclib to endocrine therapy failed to improve invasive disease-free survival in patients with hormone receptor–positive, HER2-negative breast cancer who are at high risk of relapse following neoadjuvant chemotherapy.